Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Similares en SciELO
Compartir
Gaceta mexicana de oncología
versión On-line ISSN 2565-005Xversión impresa ISSN 1665-9201
Resumen
RIVERA-CORTEZ, José de Jesús; PEREZ-PEREZ, Perla y CARDENAS-CARDENAS, Eduardo. Adverse effects of cabazitaxel at a dose of 20 mg/m2 vs. 25 mg/m2 in patients with resistant castration prostate cancer: retrospective analysis of case-series. Gac. mex. oncol. [online]. 2020, vol.19, n.1, pp.3-6. Epub 30-Abr-2021. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.19000307.
Introduction:
In patients with resistant castration prostate cancer (RCPC), the TROPIC study established cabazitaxel 25 mg/ m2 as the standard second-line chemotherapy. In order to reduce the adverse effects, the PROSELICA study evaluated whether the decrease in the dose of cabazitaxel at 20 mg/m2 was not inferior fulfilling the objective. We propose this study to know the side effects of cabazitaxel in our population
Materials and Methods:
Patients > 18 years with RCPC, treated with cabazitaxel at a dose of 20 mg/m2 and 25 mg/m2, from 2014 to 2017, in a population of Centro Médico Nacional 20 de Noviembre, ISSSTE
Results:
41 patients were recruited. In both groups the most common toxicity was diarrhea in > 90% of the patients, however, grade 3-4 diarrhea in the 20 mg/m2 cabazitaxel group was 24% compared to the 25 mg/m2 group of 31.2%. A 12% of febrile neutropenia was observed in the control group compared to none patient at a dose of 20 mg/m2
Conclusions:
In our population, better tolerance of cabazitaxel at a dose of 20 mg/m2 compared to 25 mg/m2 is corroborated, we believe that the use of such dose should be a standard, as part of the tools available for the RCPC.
Palabras llave : Cabazitaxel 20 mg/m2; Resistant castration prostate cancer; Second line; Adverse effects.